GWSG
VRDN icon

GPS Wealth Strategies Group’s Viridian Therapeutics VRDN Stock Holding History

GPS Wealth Strategies Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3
Closed – – 1057
2022
Q3 		$0 Hold
3
– – ﹤0.01% 1182
2022
Q2 		$0 Hold
3
– – ﹤0.01% 1178
2022
Q1 		$0 Hold
3
– – ﹤0.01% 1153
2021
Q4 		$0 Hold
3
– – ﹤0.01% 1114
2021
Q3 		$0 Hold
3
– – ﹤0.01% 1076
2021
Q2 		$0 Hold
3
– – ﹤0.01% 1072
2021
Q1 		$0 Buy
+3
New +$56 ﹤0.01% 968

Other funds holding VRDN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

GPS Wealth Strategies Group's VRDN Position: Q4 2022 in Review

GPS Wealth Strategies Group sold out of Viridian Therapeutics (VRDN) in Q4 2022, closing a stake of 3 shares.

GPS Wealth Strategies Group first reported a position in VRDN in Q1 2021 and held it in 7 quarters. The position peaked at $0 in Q3 2022. 122 funds tracked by Wall St. Rank hold VRDN as of Q4 2022.

  • GPS Wealth Strategies Group reported no remaining Viridian Therapeutics position as of Q4 2022 after selling out during the quarter.
  • GPS Wealth Strategies Group sold 3 Viridian Therapeutics shares in Q4 2022.
  • GPS Wealth Strategies Group first reported a position in Viridian Therapeutics in Q1 2021 and held it in 7 quarters.
  • GPS Wealth Strategies Group's Viridian Therapeutics position peaked at $0 in Q3 2022.
  • 122 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2022.

Based on GPS Wealth Strategies Group's 13F filing for Q4 2022, filed 27 Jan 2023.